Medtronic: This Dividend Aristocrat Is Just Getting Started

Medtronic is regaining momentum, driven by double-digit growth in key cardiac franchises and a raised full-year revenue outlook. MDT's pulsed-field ablation business surged, with U.S. PFA sales more than tripling, fueling overall cardiovascular strength. Management is shifting to a growth mindset, scaling manufacturing and R&D to capture underpenetrated markets, while maintaining a strong balance sheet.

Seeking Alpha • Dec 9, 2025

MDT Stock Set to Benefit From the FDA Clearance of Hugo RAS System

Medtronic gains from the FDA clearance of its Hugo RAS system, expanding U.S. access to robotic-assisted urologic surgery.

Zacks Investment Research • Dec 5, 2025

Medtronic (MDT) Upgraded to Buy: Here's Why

Medtronic (MDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Dec 5, 2025

MDT or ESLOY: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Dec 5, 2025

Prediction: 1 Healthcare Giant Set to Soar in 2026

Medtronic recently delivered strong quarterly results thanks to a fast-growing franchise. This tailwind, along with others, could help maintain the stock's momentum into 2026.

The Motley Fool • Dec 4, 2025

Medtronic announces cash dividend for third quarter of fiscal year 2026

GALWAY, Ireland , Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025.

PRNewsWire • Dec 4, 2025

Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic surgical offerings, ultimately creating a connected and integrated operating room today and into the future. GALWAY, Ireland , Dec. 3, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in surgical innovation, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures.

PRNewsWire • Dec 3, 2025

The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock

Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.

Zacks Investment Research • Dec 3, 2025

Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott

GALWAY, Ireland , Dec. 2, 2025  /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed™ systems. Following U.S. FDA clearance of the system earlier this year to enable integration with the Instinct sensor, the system is now shipping to customers across the U.S., marking a major milestone in diabetes technology and delivering a smart, seamless way to manage diabetes.

PRNewsWire • Dec 2, 2025

3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio

Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-term investors.

The Motley Fool • Nov 30, 2025